Top Banner
WELCOME TO EUFETS GMBH Your Provider of Integrated Product Development Services for Cell & Gene Therapy EUFETS GmbH - A Company of BioNTech AG
14
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: EUFETS_CompanyPresentationDEC14

WELCOME TO EUFETS GMBH

Your Provider of

Integrated Product Development Services

for Cell & Gene Therapy

EUFETS GmbH - A Company of BioNTech AG

Page 2: EUFETS_CompanyPresentationDEC14

EUFETS is part of BioNTech group

Page 3: EUFETS_CompanyPresentationDEC14

EUFETS Mission

3 / 15

Page 4: EUFETS_CompanyPresentationDEC14

OVERVIEW – OUR FACILITIES

STATE OF THE ART FACILITIES

» Located in Idar-Oberstein, Germany (1.5 hrs from Frankfurt int. Airport)

» Facility complex: >4,500 m2 (>48,000 sq ft)

» Segregated manufacturing building housing

various clean room suites classified up to grade

A/B (class 100)

» Well equipped QC laboratories

» Flexible R&D laboratories

» Significant cryogenic storage capacity

» cGMP & cGLP certified

» Biological safety level S2 (conditionally higher)

4 / 15

Page 5: EUFETS_CompanyPresentationDEC14

OVERVIEW – OUR HISTORY

E U F E T S GMBH A Company of BioNTech AG

1997 Founded as a spin-off from the Idar-Oberstein based Bone Marrow Transplantation Unit

1999 Granted a first Manufacturing licence from the local authorities for the production of stem cell products

2001 EUFETS becomes a subsidiary of Fresenius Biotech GmbH and starts expansion of its GMP facility

2003 EUFETS achieves accreditation as Good Laboratory Practice (GLP) facility

New GMP facility is certified by the local authorities for the production of cell- and gene therapy medicinal products

2003 EUFETS develops and manufactures various cell and gene therapy products for projects sponsored by Fresenius Biotech GmbH

EUFETS performs first GLP studies

2006 EUFETS establishes and strengthens its third party business and develops and produces novel products for international clients

2009 EUFETS becomes a subsidiary of BioNTech AG, Mainz

2010 EUFETS expands the technology portfolio by implementation of a manufacturing technology for in vitro transcribed RNA

2013 EUFETS acquires major pharma company as client for technology development and contract manufacturing of gene modified T cells

2014 Eufets supports several Phase II and pivotal clinical trials in cell and gene therapy

5 / 15

Page 6: EUFETS_CompanyPresentationDEC14

MANUFACTURING TRACK RECORD IN CELL & GENE THERAPY

OVERVIEW - OUR TRACK RECORD

Technology Country EUFETS Contribution

Stem cell

transplantation

Germany Manufacturing and QC of >1000 products (leukapheresis, bone marrow, cord

blood, CD34+ stem cells, donor lymphocytes)

Stem cell gene

therapy

Germany,

Switzerland,

EU

Manufacturing and QC of retroviral and lentiviral vector modified stem cells for:

• CGD

• WAS

T cell gene

therapy

Germany, EU Manufacturing and QC of retroviral and lentiviral vector modified T cells for:

• HSV-TK suicide gene therapy

• anti HIV gene Therapy

• Cancer gene therapy with CARs

Other cell therapy EU Technology development and Phase II clinical support for 2 DC manufacturing

projects

RNA production Germany • Manufacturing of > 30 batches of RNA (drug product)

• Manufacturing of > 20 batches of RNA (starting material)

Retroviral vector

production

EU, US,

Australia

• Manufacturing of > 20 different retroviral vectors for clinical application (3 SIN

vectors)

• Batch sizes of 5 to 80 liters

6 / 15

Page 7: EUFETS_CompanyPresentationDEC14

EUFETS GMBH

Services for

Preclinical Product Development

7 / 15

Page 8: EUFETS_CompanyPresentationDEC14

TECHNOLOGY TRANSFER AND PROCESS

DEVELOPMENT

DEVELOPMENT SERVICES

» Single point of contact & project management

» >600 m2 lab space of BSL up to S2/S3**

» Process development until GMP readiness

» in house retroviral vector design and optimization

» parallel small scale development work

» strong development analytics

» process optimization and scale up

» Generation of reference and animal trial material

» Well equipped for a diversity of projects:

» 10 cell culture work places (LAF, incubator, etc.)

» roller bottle incubators, 3 Wave bioreactors, Quantum

» 4 flow cytometers, 1 cell sorter, Bioprofiler etc.

» Äkta Explorer 100 chromatography skid 8 / 15

Page 9: EUFETS_CompanyPresentationDEC14

PRECLINICAL SERVICES FOR CANDIDATE PRODUCTS

» Specialized in cell based in-vitro bioanalytics

» Wide range of in-vitro models in house

» Experienced in safety and potency testing of diverse

products

» Customized services (assay development & validation)

» Analytical services available under both non-GLP and GLP

DEVELOPMENT SERVICES

9 / 15

Page 10: EUFETS_CompanyPresentationDEC14

EUFETS GMBH

GMP Services for

Clinical Product Development

10 / 15

Page 11: EUFETS_CompanyPresentationDEC14

MANUFACTURING - STATE OF THE ART FACILITIES

» GMP certified since 1999

» 500 m2 (5,300 sq ft) production area on two levels

» Level 1 optimized for aseptic handling of cell and gene

therapy products

» 6 suites classified grade C (class 10,000) or grade A/B

(class 100)

» Biological safety level of S2/S3**

» Level 2 with 4 additional suites

» Segregated lab building

» Significant product storage capacity

GMP SERVICES

11 / 15

Page 12: EUFETS_CompanyPresentationDEC14

MANUFACTURING OF CELL THERAPY PRODUCTS

» Isolation of primary human cells & subpopulations

» e.g. CD34+, CD3+ cells

» Culture, expansion, manipulation & harvest of cells

» primary human cells, human stem cells and human cell lines

» Differentiation of primary human cells

» Testing and release of the cell based medicinal product

» Cell line development

» Cell banking & cryopreservation

» Option for high intensity γ irradiation of cellular products

GMP SERVICES

12 / 15

Page 13: EUFETS_CompanyPresentationDEC14

MANUFACTURING OF GENE THERAPY PRODUCTS

» Construction of retroviral vectors in house

» Establishment of retroviral producer cell lines

» Cell banking and cryogenic storage (MCB & WCB)

» Bulk production of clinical grade retroviral vector

» batch size up to 350 liters

» concentration of bulk retroviral vector established

» Genetic modification of primary human cells

» eg.T-cells, stem cells

» Genetic modification of mammalian cell lines

» Manufacturing of ivt RNA in gramm scale

GMP SERVICES

13 / 15

Page 14: EUFETS_CompanyPresentationDEC14

THOROUGH QUALITY CONTROL AND PRODUCT

CHARACTERIZATION

» Separate quality control department ensuring compliant

testing

» Expertise in qualification and validation of assays

» Comprehensive set of analytical methodology including

» Immunocytochemistry ( eg. FACS, ELISA, cytokine release)

» Cell Biology ( eg. tests for clonogenicity, functionality)

» Retrovirology (eg. tests for RCR, infectious particles)

» Microbiology (eg. tests for sterility, mycoplasm, endotoxin)

» BioAnalytics (eg. capillary electrophoresis, qPCR)

» Network of qualified contract laboratories

» Product release by own QP for cell & gene therapy products

14 / 15

GMP SERVICES